Genetic biomarker may help identify neuroblastomas vulnerable to novel class of drugs

April 9, 2013, Dana-Farber Cancer Institute

An irregularity within many neuroblastoma cells may indicate whether a neuroblastoma tumor, a difficult-to-treat, early childhood cancer, is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors, Dana-Farber/Children's Hospital Cancer Center scientists will report at the annual meeting of the American Association for Cancer Research in Washington, April 6-10.

The findings (abstract 4622) will be discussed in a minisymposium on Tuesday, April 9, 3:50 - 4:05 p.m., ET, in Room 147, in the Washington Convention Center. The work was published in Cancer Discovery, a journal of the American Association of , on Feb. 21, 2013.

In studies with laboratory samples of neuroblastoma cells and mice with the disease, the researchers found that tumors with excess copies, or "amplification," of the gene MYCN were highly sensitive to BET bromodomain inhibitors. The findings may lead to clinical trials of the drugs in patients whose neuroblastoma tumors carry this amplification.

"BET bromodomain inhibitors are a class of drugs that, many researchers hope, may offer a new for treating patients with certain cancers," says Dana-Farber/Children's Hospital Cancer Center researcher and clinician Kimberly Stegmaier, MD, who will be presenting the research. "The challenge has been identifying biomarkers that can help direct clinical translation of these drugs by pinpointing those patients with the highest likelihood of response."

Stegmaier and her colleagues screened more than 600 cancer cell lines, each with a known set of , to see which would succumb to a prototype BET bromodomain inhibitor. They found the most susceptible cells were those with a MYCN amplification.

"Neuroblastoma is a devastating – the most common extracranial tumor of early childhood – and only a minority of children with aggressive forms of the disease are cured with currently available treatments," Stegmaier remarks. "Although prior research has shown that MYCN amplification is common in neuroblastoma, it has been an elusive drug target."

Working with Dana-Farber's James Bradner, MD, Stegmaier found that the BET bromodomain inhibitor reduced the levels of MYCN protein in lab-grown , resulting in impaired cell growth and induction of cell death. In studies of mice with MYCN-amplified neuroblastoma – including animals with a form of the disease that doesn't respond to many standard therapies – the drug had anti-tumor effects and prolonged survival.

Explore further: Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors

Related Stories

Biomarker may identify neuroblastomas with sensitivity to BET bromodomain inhibitors

February 21, 2013
Neuroblastoma, the most common malignant tumor of early childhood, is frequently associated with the presence of MYCN amplification, a genetic biomarker associated with poor prognosis. Researchers have determined that tumors ...

Scientists develop new strategy to overcome drug-resistant childhood cancer

July 11, 2012
A new drug combination could offer hope to children with neuroblastoma – one of the deadliest forms of childhood cancer – by boosting the effectiveness of a promising new gene-targeted treatment.

Study finds association between genetic mutation and age at diagnosis for common childhood cancer

March 13, 2012
Certain mutations of the gene ATRX were associated with age at diagnosis in children and young adults with advanced-stage neuroblastoma, a cancer that grows in parts of the nervous system, according to a study in the March ...

Recommended for you

T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma

January 16, 2018
WASHINGTON-(Jan. 16, 2018)-Tumors have come up with ingenious strategies that enable them to evade detection and destruction by the immune system. So, a research team that includes Children's National Health System clinician-researchers ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Dietary fat, changes in fat metabolism may promote prostate cancer metastasis

January 15, 2018
Prostate tumors tend to be what scientists call "indolent" - so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, ...

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.